Verastem (NASDAQ:VSTM) reported a global licensing agreement with Chugai Pharmaceutical (OTCPK:CHGCF) to develop rights to RAF/MEK inhibitor CH5126766 for KRAS-mutant solid tumors. Yesterday, …
In March 2019, running from $2 to more than $5, Sorrento Therapeutics (SRNE) seemed to seduce market participants. The market excitement was created by two stock catalyst. Firstly, it was related to …
With H1 2019 sales growth of 33% and double digit profit margin, Zhongchao could represent a magnificent opportunity for growth investors. It holds a significant amount of cash to finance future …
The stock market always has a few surprises in store, as any investor would attest. However, the biggest factor experts are considering as they identify the best stocks to buy for 2021 is the same factor that dominated 2020: A few of these stocks have been overbearing for a long time and simply look primed to continue their success for yet another year. …